Almaden Genomics Names New VP/Head of Business Development

Ellen Gordon has worked for more than two decades on behalf of pharmaceutical and biotech companies to deliver insights and much-needed solutions. "Her experience supporting the swift development of novel medicines makes her ideal for helping our clients leverage g.nome to accelerate drug discovery," CEO David Gascogine said.

Industry veteran Ellen Gordon has been named vice president, head of business development, by Dallas-based Almaden Genomics, a role in which she will help the company partner with clients and labs to accelerate genomic research and discovery through streamlined bioinformatics.

With more than two decades working with pharmaceutical and biotech companies, Gordon has a track record of delivering insights and much-needed solutions, the company said. And her experience helping speed development of novel medicines should boost Almaden’s g.nome, a cloud-native data analysis platform that enables pipeline iteration by scientists of all skill levels and dramatically accelerates bioinformatics development from months to just hours.

“Ellen has spent her career working with clients to analyze data and answer key business questions across the product life cycle, focusing on drug-target and biomarker discovery as well as early-stage development,” CEO David Gascogine said in a statement. “Her experience supporting the swift development of novel medicines makes her ideal for helping our clients leverage g.nome to accelerate drug discovery.”

Before Almaden, Gordon was VP of global accounts at BrightInsight, a platform for biopharma and medtech regulated digital health solutions. She also has served in the biopharmaceutical space as digital ventures lead for Memorial Sloan Kettering Cancer Center, executive director of business development for GNS Healthcare, VP of business development for Genuity Science, and VP of AlphaImpactRx.

Speeding discovery in genomic research

From promising drug development, diagnosis of genetic disease, and the realization of personalized medicine, the company said that g.nome helps speed discovery in genomic research.

The platform leverages an advanced visual drag-and-drop workflow builder and curated library of open-source tools, enabling users to have confidence in their results, get to market faster, and scale profitably.

Almaden Genomics was launched last year and is the latest in a series of spinoffs by Catalyze Dallas to speed time-to-market for technology harvested from the Fortune 100.

Catalyze launches scalable companies that it said accelerate commercialization of intellectual property sourced from the world’s most innovative global corporations to unleash the full value and potential of their investments in technology.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T